by jtcir-auto | May 9, 2023 | Press Releases
– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and commercialization partners for Macrilen® (macimorelin) in...
by jtcir-auto | May 9, 2023 | Press Releases
– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and commercialization partners for Macrilen® (macimorelin) in...
by jtcir-auto | Apr 5, 2023 | Press Releases
U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and commercialization efforts continue to move forward in European...
by jtcir-auto | Apr 5, 2023 | Press Releases
U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and commercialization efforts continue to move forward in European...
by jtcir-auto | Mar 23, 2023 | Press Releases
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025- Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go...